Max Robotics — Global Service Robot Directory + US Certification

About

Richard Colling is a pioneering researcher in the field of urologic oncology and molecular imaging, with a particular focus on prostate cancer. His major contributions center on the development and clinical translation of targeted molecular imaging agents for intraoperative guidance during radical prostatectomy. Colling led the first-in-human study of the PSMA-targeted minibody IR800-IAB2M, a groundbreaking achievement that demonstrated the feasibility of molecularly targeted fluorescence guidance during robot-assisted laparoscopic radical prostatectomy. This work, published in 2024 and already garnering 18 citations, represents a significant step toward improving surgical precision by enabling real-time visualization of prostate cancer margins. His research bridges the gap between preclinical molecular targeting and clinical surgical practice, offering the potential to reduce positive surgical margins and improve oncologic outcomes. Colling's innovative approach to combining PSMA-targeted imaging with intraoperative fluorescence has positioned him as a leading figure in the emerging field of image-guided surgery for prostate cancer, with his work laying the foundation for future clinical trials and broader adoption of molecularly targeted surgical guidance.